This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ENDP Endo International (ENDP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Endo International Stock (NASDAQ:ENDP) 30 days 90 days 365 days Advanced Chart Get Endo International alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.28▼$0.7552-Week Range N/AVolume9,967 shsAverage Volume28.19 million shsMarket Capitalization$141,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEndo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.Read More… Endo International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreENDP MarketRank™: Endo International scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Endo International. Earnings and Valuation0.0 / 5Proj. Earnings Growth-83.33% Earnings GrowthEarnings for Endo International are expected to decrease by -83.33% in the coming year, from $0.78 to $0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Endo International is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Endo International is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ENDP. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEndo International does not currently pay a dividend.Dividend GrowthEndo International does not have a long track record of dividend growth. Sustainability and ESG3.5 / 5Environmental Score-2.62 Short InterestThere is no current short interest data available for ENDP. News and Social Media0.6 / 5News Sentiment0.01 News Coverage This WeekMarketBeat has tracked 4 news articles for Endo International this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for ENDP on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Endo International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Endo International is held by insiders.Percentage Held by Institutions80.39% of the stock of Endo International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Endo International's insider trading history. Receive ENDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endo International and its competitors with MarketBeat's FREE daily newsletter. Email Address ENDP Stock News HeadlinesHarvard’s War With Trump Forces Question of How Endowments Should Be SpentApril 26 at 9:49 AM | nytimes.comEMA Endorses Expanded Use of Takeda's Adcetris (TAK) for Hodgkin Lymphoma | TAK Stock NewsApril 25 at 5:42 PM | gurufocus.comFrom Social Security to Social Prosperity?In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.April 26, 2025 | Paradigm Press (Ad)Proxy Advisory Firms Endorse Osisko’s Proposed ResolutionsApril 24 at 11:04 AM | tipranks.comAmerican Tungsten (TUNG) Endorses U.S. Executive Order on Critical MetalsApril 20, 2025 | gurufocus.comCDC Endorses GSK's Penmenvy for Adolescent VaccinationApril 16, 2025 | gurufocus.comEquinox Gold (EQX) Gains as Analysts Endorse Calibre Mining AcquisitionApril 16, 2025 | gurufocus.combluebird bio (BLUE) Board Endorses Deal Amid Ayrmid's UncertaintyApril 16, 2025 | gurufocus.comSee More Headlines ENDP Stock Analysis - Frequently Asked Questions How were Endo International's earnings last quarter? Endo International plc (NASDAQ:ENDP) released its quarterly earnings data on Thursday, November, 4th. The company reported $0.80 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.34. The firm's revenue was up 21.6% on a year-over-year basis. What other stocks do shareholders of Endo International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Endo International investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Bank of America (BAC), Micron Technology (MU) and Gilead Sciences (GILD). Company Calendar Last Earnings11/04/2021Today4/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ENDP CIK1593034 Webwww.endo.com Phone(531) 268-2000Fax800-329-3636Employees3,103Year Founded1997Profitability EPS (Most Recent Fiscal Year)($11.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-613,240,000.00 Net Margins-93.31% Pretax Margin-91.14% Return on Equity-34.25% Return on Assets6.72% Debt Debt-to-Equity RatioN/A Current Ratio1.86 Quick Ratio1.62 Sales & Book Value Annual Sales$2.99 billion Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.06 Book Value($13.60) per share Price / BookN/AMiscellaneous Outstanding Shares235,143,000Free Float232,321,000Market Cap$141,000.00 OptionableNo Data Beta1.15 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ENDP) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endo International plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Endo International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.